http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001526774-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 |
| filingDate | 1997-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2001526774-A |
| titleOfInvention | P-selectin assay and methods of use |
| abstract | (57) [Summary]nThe present invention provides a method for assessing the effect of "anti-platelet" agents on platelet activation by monitoring the levels of membrane bound P-selectin and / or soluble P-selectin in a sample from an individual. About. In one embodiment, the level of P-selectin is monitored in a sample containing platelets (eg, a blood sample, platelet-rich plasma (PRP)) using a membrane-bound P-selectin assay. In other embodiments, the level of P-selectin is monitored using a soluble P-selectin assay in a sample that has been previously depleted of platelets (eg, platelet-poor plasma (PPP) serum). Another concept of the present invention involves measuring both membrane bound P-selectin and soluble P-selectin to monitor platelet activation in patients receiving antiplatelet therapy. The method is useful for monitoring the effect of antiplatelet therapy on platelet activation status affecting levels of membrane bound P-selectin and / or soluble P-selectin. Antiplatelet therapy can be adjusted to maintain the desired level of platelet activation. In another aspect, the invention relates to a method for assessing the effect of vascular intervention, particularly coronary intervention, on platelet activation status, comprising determining the level of soluble P-selectin in a sample. Antiplatelet therapy can be initiated or adjusted to achieve a basal or other desired platelet activation state. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008249552-A |
| priorityDate | 1996-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 430.